British Journal of Cancer - Table of Contents alert Volume 109 Issue 12

TABLE OF CONTENTS Volume 109, Issue 12 (2951-3150) Published online 10 December 2013 In this issue Editorial Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Letters to the Editor Corrigendum Retraction Indexes Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Have you read the latest featured articles from British Journal of Cancer?  Read the article for FREE  They may bring articles to your attention that you might not have otherwise noticed. We hope you enjoy them. Editorial Top An unmet need: tailoring extended adjuvant endocrine therapy G Bianchini and L Gianni Br J Cancer 2013 109: 2951-2953; advance online publication, November 19, 2013; 10.1038/bjc.2013.707 Full Text Minireview Top p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy B Rao, S Lain and A M Thompson Br J Cancer 2013 109: 2954-2958; advance online publication, November 14, 2013; 10.1038/bjc.2013.702 Abstract | Full Text Clinical Studies Top The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients P Dubsky, J C Brase, R Jakesz, M Rudas, C F Singer, R Greil, O Dietze, I Luisser, E Klug, R Sedivy, M Bachner, D Mayr, M Schmidt, M C Gehrmann, C Petry, K E Weber, K Fisch, R Kronenwett, M Gnant and M Filipits on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) Br J Cancer 2013 109: 2959-2964; advance online publication, October 24, 2013; 10.1038/bjc.2013.671 Abstract | Full Text Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer L S Rigter, C E Loo, S C Linn, G S Sonke, E van Werkhoven, E H Lips, H A Warnars, P K Doll, A Bruining, I A Mandjes, M J Vrancken Peeters, J Wesseling, K G Gilhuijs and S Rodenhuis Br J Cancer 2013 109: 2965-2972; advance online publication, October 22, 2013; 10.1038/bjc.2013.661 Abstract | Full Text 18F-FDG PET/CT surveillance at 3–6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma J W Kim, J-L Roh, J S Kim, J H Lee, K-J Cho, S-H Choi, S Y Nam and S Y Kim Br J Cancer 2013 109: 2973-2979; advance online publication, October 22, 2013; 10.1038/bjc.2013.668 Abstract | Full Text Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer A Homma, T Sakashita, D Yoshida, R Onimaru, K Tsuchiya, F Suzuki, K Yasuda, H Hatakeyama, J Furusawa, T Mizumachi, S Kano, N Inamura, S Taki, H Shirato and S Fukuda Br J Cancer 2013 109: 2980-2986; advance online publication, November 5, 2013; 10.1038/bjc.2013.663 Abstract | Full Text Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system P-Y OuYang, Z Su, X-H Ma, Y-P Mao, M-Z Liu and F-Y Xie Br J Cancer 2013 109: 2987-2997; advance online publication, October 22, 2013; 10.1038/bjc.2013.659 Abstract | Full Text Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC) C Seidel, J Busch, S Weikert, S Steffens, C Bokemeyer and V Grünwald Br J Cancer 2013 109: 2998-3004; advance online publication, October 29, 2013; 10.1038/bjc.2013.662 Abstract | Full Text The effects of multidisciplinary rehabilitation: RePCa—a randomised study among primary prostate cancer patients K B Dieperink, C Johansen, S Hansen, L Wagner, K K Andersen, L R Minet and O Hansen Br J Cancer 2013 109: 3005-3013; advance online publication, October 29, 2013; 10.1038/bjc.2013.679 Abstract | Full Text Translational Therapeutics Top Human fucosyltransferase 6 enables prostate cancer metastasis to bone J Li, A D Guillebon, J-w Hsu, S R Barthel, C J Dimitroff, Y-F Lee and M R King Br J Cancer 2013 109: 3014-3022; advance online publication, October 31, 2013; 10.1038/bjc.2013.690 Abstract | Full Text HDAC inhibitor confers radiosensitivity to prostate stem-like cells F M Frame, D Pellacani, A T Collins, M S Simms, V M Mann, GDD Jones, M Meuth, R G Bristow and N J Maitland Br J Cancer 2013 109: 3023-3033; advance online publication, November 12, 2013; 10.1038/bjc.2013.691 Abstract | Full Text Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells R A McCloy, E J Shelley, C G Roberts, E Boslem, T J Biden, R I Nicholson, J M Gee, R L Sutherland, E A Musgrove, A Burgess and A J Butt Br J Cancer 2013 109: 3034-3041; advance online publication, October 31, 2013; 10.1038/bjc.2013.693 Abstract | Full Text Molecular Diagnostics Top Role of multifunctional transcription factor TFII-I and putative tumour suppressor DBC1 in cell cycle and DNA double strand damage repair M Tanikawa, O Wada-Hiraike, N Yoshizawa-Sugata, A Shirane, M Hirano, H Hiraike, Y Miyamoto, K Sone, Y Ikeda, T Kashiyama, K Oda, K Kawana, Y Katakura, T Yano, H Masai, A L Roy, Y Osuga and T Fujii Br J Cancer 2013 109: 3042-3048; advance online publication, November 14, 2013; 10.1038/bjc.2013.532 Abstract | Full Text Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion J C Sok, J A Lee, S Dasari, S Joyce, S C Contrucci, A M Egloff, B K Trevelline, R Joshi, N Kumari, J R Grandis and S M Thomas Br J Cancer 2013 109: 3049-3056; advance online publication, November 14, 2013; 10.1038/bjc.2013.624 Abstract | Full Text Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study T Aparicio, M Svrcek, A Zaanan, E Beohou, A Laforest, P Afchain, Emmanuel Mitry, J Taieb, F Di Fiore, J-M Gornet, A Thirot-Bidault, I Sobhani, D Malka, T Lecomte, C Locher, F Bonnetain and P Laurent-Puig Br J Cancer 2013 109: 3057-3066; advance online publication, November 5, 2013; 10.1038/bjc.2013.677 Abstract | Full Text KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer K G Spindler, A L Appelt, N Pallisgaard, R F Andersen and A Jakobsen Br J Cancer 2013 109: 3067-3072; advance online publication, November 21, 2013; 10.1038/bjc.2013.633 Abstract | Full Text Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer A Benard, C J H van de Velde, L Lessard, H Putter, L Takeshima, P J K Kuppen and D S B Hoon Br J Cancer 2013 109: 3073-3083; advance online publication, November 12, 2013; 10.1038/bjc.2013.654 Abstract | Full Text High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma P Bonvini, A Zin, R Alaggio, B Pawel, G Bisogno and A Rosolen Br J Cancer 2013 109: 3084-3091; advance online publication, October 22, 2013; 10.1038/bjc.2013.653 Abstract | Full Text Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis F Peng, J Jiang, Y Yu, R Tian, X Guo, X Li, M Shen, M Xu, F Zhu, C Shi, J Hu, M Wang and R Qin Br J Cancer 2013 109: 3092-3104; advance online publication, October 29, 2013; 10.1038/bjc.2013.655 Abstract | Full Text Genetics and Genomics Top Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression X Tan, Y Wang, Y Han, W Chang, T Su, J Hou, D Xu, Y Yu, W Ma, T C Thompson and G Cao Br J Cancer 2013 109: 3105-3115; advance online publication, October 24, 2013; 10.1038/bjc.2013.669 Abstract | Full Text Strong reduction of AGO2 expression in melanoma and cellular consequences D Völler, J Reinders, G Meister and A-K Bosserhoff Br J Cancer 2013 109: 3116-3124; advance online publication, October 29, 2013; 10.1038/bjc.2013.646 Abstract | Full Text Letters to the Editor Top Neutrophil to lymphocyte ratio may be predict of mortality in all conditions S Balta, S Demirkol, M Unlu, Z Arslan and T Celik Br J Cancer 2013 109: 3125-3126; advance online publication, October 1, 2013; 10.1038/bjc.2013.598 Full Text Reply: Comment on ‘A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients’ J Szkandera, M Pichler, M Stotz and A Gerger Br J Cancer 2013 109: 3126-3127; advance online publication, October 1, 2013; 10.1038/bjc.2013.599 Full Text Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’ F Bibeau, H Gil, F Castan and F Boissière-Michot Br J Cancer 2013 109: 3127-3129; advance online publication, October 24, 2013; 10.1038/bjc.2013.651 Full Text Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab’ M Schirripa, F Loupakis, L Pollina, C Cremolini, G Pasquini and A Falcone Br J Cancer 2013 109: 3129-3130; advance online publication, October 24, 2013; 10.1038/bjc.2013.652 Full Text Corrigendum Top DICER1 hotspot mutations in non-epithelial gonadal tumours L Witkowski, J Mattina, S Schönberger, M J Murray, C S Choong, D G Huntsman, J S Reis-Filho, W G McCluggage, J C Nicholson, N Coleman, G Calaminus, D T Schneider, J Arseneau, C J R Stewart and W D Foulkes Br J Cancer 2013 109: 3131; 10.1038/bjc.2013.782 Full Text Retraction Top DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers M Suzuki, H Shigematsu, D S Shames, N Sunaga, T Takahashi, N Shivapurkar, T Iizasa, E P Frenkel, J D Minna, T Fujisawa and A F Gazdar Br J Cancer 2013 109: 3132; 10.1038/bjc.2013.776 Full Text Indexes Top Author Index for Volume 109 Br J Cancer 2013 109: 3133-3144; 10.1038/bjc.2013.772 Full Text Keyword Index for Volume 109 Br J Cancer 2013 109: 3145-3150; 10.1038/bjc.2013.773 Full Text Advertisement Have you read these highly cited articles from British Journal of Cancer?  Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers   Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer  Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.